Becton, Dickinson and Co.  

(Public, NYSE:BDX)   Watch this stock  
Find more results for BDX
118.24
+0.40 (0.34%)
Jul 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 118.17 - 118.94
52 week 96.73 - 120.66
Open 118.17
Vol / Avg. 492,122.00/646,373.00
Mkt cap 22.84B
P/E 24.92
Div/yield 0.55/1.84
EPS 4.75
Shares 193.20M
Beta 0.79
Inst. own 86%
Jul 31, 2014
Q3 2014 Becton Dickinson and Co Earnings Release - 9:30AM EDT - Add to calendar
Jul 31, 2014
Q3 2014 Becton Dickinson and Co Earnings Call - 8:00AM EDT - Add to calendar
Jun 10, 2014
BD at Goldman Sachs Healthcare Conference
Jun 4, 2014
BD at Jefferies Global Healthcare Conference
May 7, 2014
BD at Deutsche Bank Healthcare Conference
May 1, 2014
Q2 2014 Becton Dickinson and Co Earnings Release
May 1, 2014
Q2 2014 Becton Dickinson and Co Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 13.85% 11.53%
Operating margin 18.39% 15.57%
EBITD margin - 26.86%
Return on average assets 9.48% 7.90%
Return on average equity 22.15% 20.24%
Employees 30,000 -
CDP Score - 69 B

Address

1 Becton Drive
FRANKLIN LAKES, NJ 07417-1880
United States - Map
+1-201-8476800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces a range of medical devices, which are used in a range of healthcare settings. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells. BD Diagnostics provides products for the safe collection and transport of diagnostics specimens. On March 11, 2013, the Company acquired a 100% interest in Cato Software Solutions (Cato).

Officers and directors

Vincent A. Forlenza Chairman of the Board, President, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Christopher R. Reidy Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 56
Bio & Compensation  - Reuters
Alexandre Conroy President, Europe, EMA and the Americas
Age: 50
Bio & Compensation  - Reuters
James Lim President, Greater Asia
Age: 49
Bio & Compensation  - Reuters
William A. Kozy Chief Operating Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gary M. Cohen Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nabil Shabshab Senior Vice President, Chief Marketing Officer
Age: 48
Bio & Compensation  - Reuters
Jeffrey S. Sherman Senior Vice President, General Counsel
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jerome V. Hurwitz Senior Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Stephen Sichak Jr. Senior Vice President - Integrated Supply Chain
Age: 56
Bio & Compensation  - Reuters